₹-5.20
(Market cap
₹1,862 Cr
Recently Viewed
Clear AllMarket cap
₹1,862 Cr
Revenue (TTM)
₹868 Cr
P/E Ratio
27.9
P/B Ratio
3.4
Div. Yield
0.7 %
Quality Score
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
₹67 Cr
ROE
12.9 %
ROCE
17.1 %
Industry P/E
29.06
EV/EBITDA
15.2
Debt to Equity
0.1
Book Value
₹260.2
EPS
₹31.8
Face value
5
Shares outstanding
21,106,229
CFO
₹343.32 Cr
EBITDA
₹504.16 Cr
Net Profit
₹320.41 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Windlas Biotech
| 10.5 | 20.8 | 10.9 | -17.6 | 51.8 | -- | -- |
|
BSE Healthcare
| 0.1 | 2.8 | 5.2 | 3.6 | 24.0 | 13.2 | 10.8 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
|---|---|---|---|---|
|
Windlas Biotech
| -23.8 | 118.5 | 71.4 | -9.4 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Windlas Biotech
|
878.4 | 1,861.6 | 868.3 | 66.8 | 8.5 | 12.8 | 27.9 | 3.4 |
| 2,779.2 | 34,689.6 | 5,201.6 | 1,014.6 | 22.9 | 25 | 34.2 | 7.6 | |
| 8,440.0 | 21,108.0 | 2,177.5 | 200.9 | 11.3 | 26.5 | 105.1 | 25.4 | |
| 1,752.5 | 13,325.2 | 2,089.5 | 622.0 | 31.3 | 20.4 | 21.7 | 4.0 | |
| 1,631.0 | 9,965.7 | 1,196.4 | 149.4 | -- | 27.5 | 66.7 | 14.2 | |
| 1,352.8 | 18,721.3 | 3,078.2 | 469.4 | 26.4 | 14.9 | 43.4 | 5.2 | |
| 1,977.8 | 31,699.9 | 4,193.0 | 753.8 | 22.7 | 20.8 | 42.1 | 7.9 | |
| 4,764.1 | 21,787.4 | 2,482.3 | 853.6 | 33.7 | 18.9 | 25.5 | 5.5 | |
| 5,132.9 | 8,522.0 | 1,348.5 | 293.5 | 28.1 | 50.7 | 29 | 12.2 | |
| 1,002.1 | 9,233.9 | 4,725.6 | 528.7 | 14.9 | 20.7 | 18.1 | 3.1 |
Sigachi Industries IPO: Information analysis
6 min read•By Arul Selvan and Udhayaprakash
3 min read•By Udhayaprakash
6 min read•By Arul Selvan
Windlas Biotech Limited, a contract development and manufacturing organization (CDMO), manufactures and trades in pharmaceutical products in India and internationally. The company offers CDMO services, including product discovery, product... development, licensing, and commercial manufacturing of generic products. It manufactures nutraceutical supplement products. In addition, the company manufactures tablets, capsules, pouches, sachets, and liquid bottles; and generic products portfolio comprises fixed dosage combinations, fixed dosage plus modified release combinations, customized generics, and chewable or dispersible. The company was incorporated in 2001 and is based in Gurugram, India. Read more
Incorporated
2001
Chairman
Vivek Dhariwal
Managing Director
Hitesh Windlass
Headquarters
Dehradun, Uttarakhand
Website
Looking for more details about Windlas Biotech Ltd.’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
The share price of Windlas Biotech Ltd is ₹878.35 (NSE) and ₹882.00 (BSE) as of 22-Apr-2026 IST. Windlas Biotech Ltd has given a return of 51.81% in the last 3 years.
The P/E ratio of Windlas Biotech Ltd is 27.89 times as on 22-Apr-2026, a 4 discount to its peers’ median range of 29.06 times.
The P/B ratio of Windlas Biotech Ltd is 3.39 times as on 22-Apr-2026, a 25 discount to its peers’ median range of 4.53 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
35.78
|
4.36
|
|
2024
|
18.31
|
2.39
|
|
2023
|
11.06
|
1.18
|
|
2022
|
12.02
|
1.17
|
|
2021
|
0.00
|
0.00
|
The 52-week high and low of Windlas Biotech Ltd are Rs 1,097.90 and Rs 697.40 as of 22-Apr-2026.
Windlas Biotech Ltd has a market capitalisation of ₹ 1,862 Cr as on 22-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Windlas Biotech Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.